Drug Profile


Alternative Names: Ecteinascidin; Ecteinascidin-743; ET-743; NSC-684766; Yondelis

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator University of Illinois
  • Developer European Organisation for Research and Treatment of Cancer; Johnson & Johnson; PharmaMar; Taiho Pharmaceutical
  • Class Antineoplastics; Dioxoles; Small molecules; Tetrahydroisoquinolines
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors; Macrophage inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Soft tissue sarcoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer; Soft tissue sarcoma
  • Phase III Fallopian tube cancer; Peritoneal cancer
  • Phase II Liposarcoma; Meningioma; Mesothelioma
  • No development reported Breast cancer; Prostate cancer

Most Recent Events

  • 23 Mar 2017 Institut Bergonié, AstraZeneca and PharmaMar plan the TRAMUNE phase I trial for Ovarian cancer and Soft tissue sarcoma (Combination therapy, Metastatic disease, Late-stage disease, Inoperable/unresectable, Second-line therapy or greater) in France (NCT03085225)
  • 10 Mar 2017 Fred Hutchinson Cancer Research Center and National Cancer Institute plan a phase I/II trial for Leiomyosarcoma and Liposarcoma (Metastatic disease, Combination therapy, Late-stage disease) in USA (NCT03074318)
  • 27 Apr 2016 National Institute for Health and Clinical Excellence (NICE) does not recommend trabectedin (in combination with pegylated liposomal doxorubicin hydrochloride) for ovarian cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top